phat 15(4): e1

Research Article

Type 2 diabetes patients assessment of the COMODITY12 mHealth system.

Download917 downloads
  • @ARTICLE{10.4108/icst.pervasivehealth.2015.259283,
        author={Przemyslaw Kardas and Krzysztof Lewandowski},
        title={Type 2 diabetes patients assessment of the COMODITY12 mHealth system.},
        journal={EAI Endorsed Transactions on Pervasive Health and Technology},
        volume={1},
        number={4},
        publisher={EAI},
        journal_a={PHAT},
        year={2015},
        month={8},
        keywords={mhealth, comodity12, diabetes},
        doi={10.4108/icst.pervasivehealth.2015.259283}
    }
    
  • Przemyslaw Kardas
    Krzysztof Lewandowski
    Year: 2015
    Type 2 diabetes patients assessment of the COMODITY12 mHealth system.
    PHAT
    EAI
    DOI: 10.4108/icst.pervasivehealth.2015.259283
Przemyslaw Kardas1,*, Krzysztof Lewandowski2
  • 1: First Department of Family Medicine, Medical University of Lodz
  • 2: Department of Endocrinology & Metabolic Diseases, Medical University of Lodz
*Contact email: przemyslaw.kardas@umed.lodz.pl

Abstract

Background: Patient acceptance is one of the major barriers toward widespread use of mHealth. The aim of this study was to assess patients’ experience with their use of COMMODITY12 telehealth system. Methods: DM2 patients assessed COMMODITY12 system after its 6 weeks’ long use within clinical trial. Patients opinions were collected with 7-item questionnaire, assessing different aspects of system use, as well as EuroQol-5D-5L generic questionnaire, assessing health-related quality of life. Results: Thirty patients (female, 13, male, 17, mean age +/- SD 59.9 +/- 5.3) completed study. All dimensions of experience with system use were assessed well, with maximum values for clearness of instructions, and ease of use (4.80, and 4.63, respectively). Health related quality of life, as assessed with general utility measure, improved significantly (P<0.05). Conclusions: Study proved that the COMODITY12 system is accepted well by type 2 diabetes patients taking part in clinical trial. Nevertheless, before future commercialisation of the system, several minor problems identified during the study need to be addressed.